glp 1 receptor agonist drugs Table from Glucagon-Like Peptide-1 (GLP-1) Agonists Drug Class Review Evolution of GLP‐1 Receptor Agonists

Retrieved August 21, 2025, from Bozick, R., Donofry, S

Human research remains limited but is expanding

Strength: confirm whether the tablets are Jardiance 10 mg or Jardiance 25 mg

Medicare Part D, or prescription drug plans, already cover some GLP-1s for conditions like diabetes and cardiovascular disease, but federal law has banned coverage solely for obesity

Shift could reflect a changing demand away from oncology toward addressing metabolic disorders GLP1 agonist drugs transformed the weight loss and diabetes landscape in 2023, propelled by robust clinical trial results and a surge in endorsements from celebrities and influencers

Semaglutide is a glucagon-like peptide 1 receptor agonist used to improve metabolic health and support weight loss as an adjunct to lifestyle changes